http://medcitynews.com/2012/07/migraine-patch-application-resubmitted-for-fda-approval/
NuPathe (NASDAQ:PATH), a biopharmaceutical company, has resubmitted a new drug application for its migraine patch to the U.S. Food and Drug Administration after resolving issues raised in a complete response letter last year.
The Zelrix transdermal patch is designed to transmit sumatriptan via electrical charge through the skin in a drug-delivery method known as iontophoresis. The method, designed to speed up the delivery process, was chosen since one symptom migraine headache sufferers experience is nausea, which makes oral medication a challenge.
Jane Hollingsworth, NuPathe’s CEO, said she expects a six-month review by the FDA.
“With the additional data and enhancements made to the patch, we have submitted a strong application and have an even more attractive commercial opportunity designed to address the needs of the nearly half of migraine patients who frequently experience both headache pain and migraine-related nausea,” a company statement said.Among the Conshohocken, Pennsylvania company’s investors are Quaker BioVentures, which holds a 22 percent stake; Safeguard Scientifics (NYSE:SFE); Battelle Ventures; and GlaxoSmithKlein‘s (NYSE:GSK) venture capital arm, SROne.
Tags: NuPathe, Pennsylvania, pharmaceuticals, PHI
Took me time to read all the comments, but I truly loved the article. It proved to be really useful to me and I am sure to all of the commenter here! It is usually good when you cannot only be informed, but additionally engaged! I am sure you had joy writing this article.
ReplyDeletekit de xenon